Feature | April 08, 2014

SCAI Issues List of Tests, Treatments to Avoid as Part of Choosing Wisely Campaign

SCAI’s list will help patients and physicians work together to determine the best course of care

SCAI ACC.14 Choosing Wisely Campaign Tests Treatments to Avoid Cath Lab

April 8, 2014 — The Society for Cardiovascular Angiography & Interventions (SCAI) issued a list of five specific, evidence-based recommendations that should be avoided in the care of patients who have, or are at risk for, cardiovascular disease. SCAI’s list was developed as part of Choosing Wisely, an initiative of the ABIM Foundation, to help physicians and patients make wise decisions together about the most appropriate care based on individual situations.

SCAI’s list includes the following five recommendations:

• Avoid routine stress testing after percutaneous coronary intervention (PCI) without specific clinical indications.

• Avoid coronary angiography in post–coronary artery bypass graft (CABG) and post-PCI patients who are asymptomatic, or who have normal or mildly abnormal stress tests and stable symptoms not limiting quality of life.

• Avoid coronary angiography for risk assessment in patients with stable ischemic heart disease who are unwilling to undergo revascularization or who are not candidates for revascularization based on co-morbidities or individual preferences.

• Avoid coronary angiography to assess risk in asymptomatic patients with no evidence of ischemia or other abnormalities on adequate non-invasive testing.\

• Avoid PCI in asymptomatic patients with stable ischemic heart disease without the demonstration of ischemia on adequate stress testing or with abnormal fractional flow reserve testing.

“We believe this list will spur conversations between heart patients and their physicians to make wise decisions about care based on their individual situation,” said James C. Blankenship, M.D., FSCAI, 2013-14 vice president of SCAI. “Our goal is to improve care for the patient and eliminate unnecessary tests and procedures.”

SCAI’s list is based on guidelines and appropriate use criteria developed by SCAI, the American College of Cardiology (ACC), American Heart Association (AHA) and other professional societies. All of the tests and procedures on SCAI’s list have been deemed to be “inappropriate” or “rarely appropriate,” according to the latest appropriate use criteria, or are “not recommended,” according to the most current professional guidelines. SCAI selected these items because appropriate use criteria and guidelines have been carefully vetted, adjudicated and agreed upon by experts from many societies.

“SCAI has shown tremendous leadership by releasing its list of tests and procedures they say are commonly done in invasive/interventional cardiology, but aren’t always necessary,” said Richard J. Baron, M.D., president and CEO of the ABIM Foundation. “The content of this list and all of the others developed through this effort are helping physicians and patients across the country engage in conversations about what care they need, and what we can do to reduce waste and overuse in our health care system.”

To date, nearly 100 national and state medical specialty societies, regional health collaboratives and consumer partners have joined the conversations about appropriate care. With the release of these new lists, the campaign will have covered more than 250 tests and procedures that specialty society partners say are overused and inappropriate, and that physicians and patients should discuss.

“Discussion between the physician and the patient and patient’s family is the foundation for delivering optimal, effective care,” said SCAI 2013-14 President Ted A. Bass, M.D., FSCAI. “Clinical judgment remains critical in determining the best course of care for the individual patient, with the complementary use of guidelines and appropriate use criteria.”

The Choosing Wisely campaign reaches millions of consumers nationwide through a stable of consumer and advocacy partners, led by Consumer Reports — the world’s largest independent product-testing organization — which has worked with the ABIM Foundation to distribute patient-friendly resources for consumers and physicians to engage in these important conversations.

For more information: www.SCAI.org, www.ChoosingWisely.org

 

Related Content

Edwards, Sapien 3 transcatheter heart valve, Canada, approval
News | Heart Valve Technology| July 27, 2016
Edwards Lifesciences Corp. announced that Health Canada has approved the Edwards Sapien 3 transcatheter heart valve for...
PCI outcomes, public reporting, high-risk patients, JAMA Cardiology, Beth Israel Deaconess Medical Center study
News | Cath Lab| July 27, 2016
July 27, 2016 — A number of states mandate public reporting of mortality outcomes following certain cardiac procedure
News | Genetic Testing| July 26, 2016
July 26, 2016 — A new study has identified a genetic error that weakens the aorta, placing patients with this and sim
Abbott, Absorb bioresorbable stent, dissolving, UAB, University of Alabama at Birmingham, first in state
News | Stents Bioresorbable| July 26, 2016
On July 20, Massoud Leesar, M.D., of University of Alabama at Birmingham Hospital implanted a patient with Absorb, the...
CMS, Overall Hospital Quality Star Rating, national distribution, quailty of care
News | Business| July 26, 2016
July 25, 2016 — The Centers for Medicare and Medicaid Services (CMS) announced that it expects to launch its new Over
Stryker Sustainability Solutions, Angiodynamics Soft Vu Omni Flush Angiographic Catheters, recall
News | Angiographic Catheter| July 25, 2016
Stryker Sustainability Solutions (formerly Ascent Healthcare Solutions) is recalling Angiodynamics Soft Vu Omni Flush...
Million Hearts Cardiovascular Disease Risk Reduction Model, CMS, reduce heart attacks and strokes, participants
News | Patient Engagement| July 22, 2016
July 22, 2016 — The Centers for Medicare & Medicaid Services (CMS) recently announced 516 awardees in 47 states,
heart failure, after first heart attack, cancer risk, JACC study
News | Cardiac Diagnostics| July 21, 2016
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared...
Absorb, bioresorbable stent, BVS

The Abbott Absorb stent gained FDA clearance in July 2016. It has metallic markers at each end so it can be visualized for proper positioning under angiographic X-ray imaging. 

Feature | Stents Bioresorbable| July 21, 2016 | Alphonse Ambrosia, D.O.
Some have labeled bioresorbable scaffolds (BRS), also known as bioresorbable stents, as the fourth evolution of inter
Sponsored Content | Videos | Inventory Management| July 19, 2016
You have bigger priorities than managing inventory.
Overlay Init